Reocclusion after successful endovascular treatment in acute ischemic stroke: systematic review and meta-analysis.

Background: Endovascular treatment (EVT) is the standard of care for selected patients with acute ischemic stroke (AIS) due to large vessel occlusion (LVO).

Objective: To systematically review the available data on: (1) incidence, predictors, and outcomes of patients with reocclusion after successful EVT for AIS and, (2) the characteristics, complications, and outcomes of patients with reocclusion treated with repeated EVT (rEVT) within 30 days of the first procedure.

Methods: PubMed was searched (between January 2012 and April 2021) to identify studies reporting reocclusion following successful EVT (Thrombolysis in Cerebral Infarction ≥2b) in patients with AIS due to LVO.

A little leak goes a long way! 5-Year-outcome after transcatheter aortic valve implantation.

Mild paravalvular leak after TAVR is associated with increased 5-year mortality. Current noninvasive and invasive prediction models for mortality may only hold for short term outcomes. Other imaging modalities aside from transthoracic echocardiography should be strongly considered when assessing paravalvular leak, regardless of severity.

Daratumumab for the Treatment of Multiple Myeloma: A Review of Clinical Applicability and Operational Considerations.

Objective: To review the available data for the efficacy and safety of daratumumab in the treatment of multiple myeloma (MM), both in the newly diagnosed and relapsed/refractory settings, as well as provide additional guidance to clinicians on operational, safety, and supportive care considerations.

Data Sources: A literature search of PubMed (1966 to October 2021) was conducted using the keywords , , and . Data were also obtained from prescribing information and unpublished abstracts from meetings.

Repeated Mechanical Endovascular Thrombectomy for Recurrent Large Vessel Occlusion: A Multicenter Experience.

Background And Purpose: Mechanical thrombectomy (MT) is now the standard of care for large vessel occlusion (LVO) stroke. However, little is known about the frequency and outcomes of repeat MT (rMT) for patients with recurrent LVO.

Methods: This is a retrospective multicenter cohort of patients who underwent rMT at 6 tertiary institutions in the United States between March 2016 and March 2020.

Antibody treatment in multiple myeloma.

Antibody therapy, which has become a critical option in the treatment of multiple myeloma (MM), includes monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies. Anti-CD38 and anti-SLAMF7 monoclonal antibodies were the first to enter the MM portfolio as treatment options for relapsed/ refractory MM. More recently, daratumumab has become important in the treatment of newly diagnosed MM, and a subcutaneous formulation has been approved.

Current developments in the combination therapy of relapsed/refractory multiple myeloma.

Introduction: Therapy for patients with multiple myeloma has improved dramatically over the past decade following the introduction of novel agents and combinations across the disease spectrum. When relapse or refractory disease develops, non-cross-resistant drugs, most often used in multidrug regimens, have provided significant improvements in patient outcomes. Despite these advances, myeloma remains incurable and additional therapeutic approaches, based on emerging molecular and cellular biology, are moving rapidly through development phases.

New and Worsening Long-term Immune-Related Adverse Events with PD-1/PD-L1 Pathway Agents in Patients with Cancer.

Study Objectives: Immune checkpoint inhibitors have produced durable responses across a variety of cancers. Although programmed cell death protein 1 (PD-1) and its ligand (PD-L1) inhibitors activate T cells against tumor cells, they may also cause autoimmune-like toxicities termed immune-related adverse events (irAEs). Although much is known regarding irAEs that occur early during treatment, data on the long-term toxicity profile of these agents are more limited.

MR Imaging-Guided Focal Treatment of Prostate Cancer: An Update.

Focal treatment of prostate cancer has evolved from a concept to a practice in the recent few years and is projected to fill an existing need, bridging the gap between conservative and radical traditional treatment options. With its low morbidity and rapid recovery time compared with whole-gland treatment alternatives, focal therapy is poised to gain more acceptance among patients and health care providers. As our experience with focal treatment matures and evidence continues to accrue, the landscape of this practice might look quite different in the future.

Creating a Clinical Interventional MRI Service.

The expansive technological developments that occurred over the past decades have clearly moved the field of Interventional MRI beyond the arena of the "proof of concept" to a viable option for minimally invasive diagnosis and therapy. State-of-the-art MRI technology can currently be employed to identify an occult target pathology, confidently steer an interventional device into complex anatomy, accurately deliver a device, drug, or energy, and/or monitor the real time effect of a treatment. Implementing a full-scope interventional MRI service requires substantial physical and conceptual modifications of the traditional diagnostic MRI environment.

Magnetic Resonance Image-Guided Focal Prostate Ablation.

Prostate cancer is the most common cancer (other than skin cancer) in American men, with one in seven men being diagnosed with this disease during his lifetime. The estimated number of new prostate cancer cases in 2016 is 180,890. For the first time, imaging has become the center of the search for contained, intraglandular, small-volume, and unifocal disease, and an increasing number of academic institutions as well as private practices are implementing programs for prostate multiplanar magnetic resonance imaging (MRI) as parts of their routine offerings.

Valve Type, Size, and Deployment Location Affect Hemodynamics in an In Vitro Valve-in-Valve Model.

Objectives: The purpose of this study was to optimize hemodynamic performance of valve-in-valve (VIV) according to transcatheter heart valve (THV) type (balloon vs. self-expandable), size, and deployment positions in an in vitro model.

Background: VIV transcatheter aortic valve replacement is increasingly used for the treatment of patients with a failing surgical bioprosthesis.

Volumetric Single-Beat Coronary Computed Tomography Angiography: Relationship of Image Quality, Heart Rate, and Body Mass Index. Initial Patient Experience With a New Computed Tomography Scanner.

Background: Cardiac computed tomography (CT) image quality (IQ) is very important for accurate diagnosis. We propose to evaluate IQ expressed as Likert scale, signal-to-noise ratio (SNR), and contrast-to-noise ratio (CNR) from coronary CT angiography images acquired with a new volumetric single-beat CT scanner on consecutive patients and assess the IQ dependence on heart rate (HR) and body mass index (BMI).

Methods: We retrospectively analyzed the data of the first 439 consecutive patients (mean age, 55.

How Can We Help a Patient With a Small Failing Bioprosthesis?: An In Vitro Case Study.

Objectives: The aim of this study was to investigate the hemodynamic performance of a transcatheter heart valve (THV) deployed at different valve-in-valve positions in an in vitro model using a small surgical bioprosthesis.

Background: Patients at high surgical risk with failing 19-mm surgical aortic bioprostheses are not candidates for valve-in-valve transcatheter aortic valve replacement, because of risk for high transvalvular pressure gradients (TVPGs) and patient-prosthesis mismatch.

Methods: A 19-mm stented aortic bioprosthesis was mounted into the aortic chamber of a pulse duplicator, and a 23-mm low-profile balloon-expandable THV was deployed (valve-in-valve) in 4 positions: normal (bottom of the THV stent aligned with the bottom of the surgical bioprosthesis sewing ring) and 3, 6, and 8 mm above the normal position.

Interventional Magnetic Resonance Imaging Clinic: The Emory University Experience.

In this article, we share our experience in establishing a clinic-based practice for MR imaging-guided interventions. Clinic resources and operational logistics are described and our institutional cost analysis for supporting the clinic activity is provided. We highlight the overall value of the clinic model in transitioning the field of interventional MR imaging from the "proof-of-concept" to the "working model" era and engage in a detailed discussion of our experience with the positive impact of the clinic on streamlining the procedural workflow, increasing awareness of the technology, expanding referral bases, and boosting the satisfaction of both patients and referring services.

Carotid artery access for transcatheter aortic valve replacement.

We report three patients who had successful transcatheter aortic valve replacement (TAVR) via carotid artery access. None were candidates for thoracotomy (including minimal access incisions) and had no other vascular access sites that would accommodate the transcatheter valve sheath. Antegrade carotid perfusion and retrograde insertion of the delivery sheath maintained cerebral blood flow without sequelae.

MRI-guided musculoskeletal soft tissue interventions.

This article highlights some of current state-of-the-art applications of interventional magnetic resonance imaging (MRI) technology pertaining to the musculoskeletal soft tissues. The rationale for the use of these techniques is to provide modes of minimally invasive diagnosis and/or therapy for a subset of patients whose lesions are not approachable by the traditional modes of interventional radiology and to introduce methods to mark subtle and infiltrative lesions to improve the outcomes of subsequent surgery or radiation therapy. These techniques build on the inherent attributes of MRI, particularly the high soft tissue contrast that made MRI the current mainstay diagnostic modality to identify and characterize musculoskeletal soft tissue lesions.

Variation in physician deep vein thrombosis prophylaxis attitudes and practices at an academic tertiary care center.

Background: Deep vein thrombosis (DVT) remains a major cause of in-hospital morbidity and mortality. Effective DVT prophylaxis is available but underutilized. We sought to describe physician understanding of DVT epidemiology and prophylaxis practices.

Perfusion technique for perfusion-assisted direct coronary artery bypass (PADCAB).

The role for the perfusionist has changed at many institutions that perform Off-Pump Coronary Artery Bypass (OPCAB). Surgeons at our hospitals have adapted a technique called Perfusion-Assisted Direct Coronary Bypass (PADCAB) (1). A simple circuit and pump have been devised for the perfusionist to deliver arterial blood to the myocardium immediately after the completion of the distal coronary anastomosis.